SummaryIn the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
Objective: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
SummaryIn the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-I...
In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) du...
BACKGROUND: The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IO...
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
Objective: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
SummaryIn the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-I...
In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) du...
BACKGROUND: The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IO...
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
Objective: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose...